Chimonas Marc-Andre R, Baggett Henry C, Parkinson Alan J, Muth Pam T, Dunaway Eitel, Gessner Bradford D
US Centers for Disease Control and Prevention, Office of Workforce and Career Development, Epidemic Intelligence Service Officer, Alaska Division of Public Health, Anchorage, Alaska 99524, USA.
Helicobacter. 2006 Jun;11(3):159-67. doi: 10.1111/j.1523-5378.2006.00395.x.
Alaska Native children have high Helicobacter pylori infection and iron deficiency prevalences, and their average height-for-age is lower than US reference populations. During a clinical trial to determine the impact of H. pylori treatment on iron deficiency, we evaluated the effects of H. pylori infection and treatment on growth.
We measured height and weight for children aged 7-11 years in western Alaska using village-based measuring devices. H. pylori infection was determined by urea breath test and iron deficiency using serum ferritin. Children with H. pylori infection and iron deficiency entered the treatment phase and received iron alone or iron plus triple therapy for H. pylori. Follow-up evaluations occurred at 2, 8, and 14 months. We evaluated the association between baseline H. pylori infection and growth; among children in the treatment phase, we also assessed the effect of H. pylori resolution on growth.
At baseline, 566 (87.1%) of 650 children were infected with H. pylori. Neither height and weight, nor body mass index differed by H. pylori infection status. Of 189 children in the treatment phase, 20 (10.6%) were uninfected at all three follow-up periods, and 54 (28.6%) were uninfected for one or two periods. Compared with continuously infected children, children in these two groups had little evidence of improvements in any of the measured growth outcomes.
H. pylori infection is not related to growth among Alaska Native children aged 7-11 years. Growth deficiency should not be considered an indication for H. pylori therapy.
阿拉斯加原住民儿童幽门螺杆菌感染率和缺铁患病率较高，且他们的年龄别平均身高低于美国参考人群。在一项确定幽门螺杆菌治疗对缺铁影响的临床试验中，我们评估了幽门螺杆菌感染和治疗对生长的影响。
我们使用基于村庄的测量设备，测量了阿拉斯加西部7至11岁儿童的身高和体重。通过尿素呼气试验确定幽门螺杆菌感染情况，通过血清铁蛋白确定缺铁情况。感染幽门螺杆菌且缺铁的儿童进入治疗阶段，单独接受铁剂治疗或接受铁剂加幽门螺杆菌三联疗法。在2个月、8个月和14个月时进行随访评估。我们评估了基线幽门螺杆菌感染与生长之间的关联；在治疗阶段的儿童中，我们还评估了幽门螺杆菌清除对生长的影响。
基线时，650名儿童中有566名（87.1%）感染了幽门螺杆菌。幽门螺杆菌感染状态对身高、体重和体重指数均无影响。在189名治疗阶段的儿童中，20名（10.6%）在所有三个随访期均未感染，54名（28.6%）在一个或两个时期未感染。与持续感染的儿童相比，这两组儿童在任何测量的生长指标上几乎没有改善的迹象。
7至11岁阿拉斯加原住民儿童的幽门螺杆菌感染与生长无关。生长不足不应被视为幽门螺杆菌治疗的指征。
